Cholest-5-ene-3,4-diol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Cholest-5-ene-3,4-diol
• 英文别名: 10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,4-diol
• 化学式: C₂₇H₄₆O₂
• 分子量: 402.7
• InChiKey: CZDKQKOAHAICSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Use of endogenous metabolites for early diagnosing sepsis
  申请人：BIOCRATES Life Sciences AG

  公开号：EP2339352A1

  公开（公告）日：2011-06-29

  The present invention relates to a use of one or a plurality of endogenous target metabolites for predicting a likelihood of an onset of a sepsis from a biological sample of a mammalian subject in vitro, wherein said endogenous target metabolites have a molecular mass less than 1500 Da and are selected from the group of oxysterols.

  本发明涉及使用一种或多种内源性目标代谢物来预测体外哺乳动物生物样本中败血症发生的可能性，其中所述内源性目标代谢物的分子质量小于 1500 Da，并且选自氧甾醇组。
• [EN] USE OF ENDOGENOUS METABOLITES FOR EARLY DIAGNOSING SEPSIS<br/>[FR] UTILISATION DE MÉTABOLITES ENDOGÈNES POUR UN DIAGNOSTIC PRÉCOCE DE LA SEPSIE
  申请人：BIOCRATES LIFE SCIENCES AG

  公开号：WO2011080184A1

  公开（公告）日：2011-07-07

  The present invention relates to a use of a plurality of endogenous target metabolites for predicting a likelihood of an onset of a sepsis from a biological sample of a mammalian subject in vitro, wherein said endogenous target metabolites have a molecular mass less than 1500 Da and are selected from the group of oxysterols.